CD30 Antibody (B-10): sc-514271
- CD30 Antibody (B-10) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- specific for an epitope mapping between amino acids 21-43 at the N-terminus of CD30 of human origin
- recommended for detection of CD30 long form of human origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for CD30 Antibody (B-10) for WB applications. These reagents are now offered in bundles with CD30 Antibody (B-10) (see ordering information below).
QUICK LINKS
SEE ALSO...
CD30 Antibody (B-10) is a mouse monoclonal IgG1 antibody that detects CD30 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). CD30 is a member of the tumor necrosis factor receptor family and is primarily expressed on activated T and B lymphocytes, as well as neoplastic cells associated with Hodgkin′s lymphoma and other hematologic malignancies. The presence of CD30 on these cells serves as a marker for diagnosis and prognosis in various lymphoproliferative disorders. Upon binding with CD30L, CD30 initiates signaling pathways that can lead to cell proliferation, survival, and differentiation, highlighting CD30′s role in immune regulation and potential therapeutic targeting. CD30 undergoes post-translational modifications, including glycosylation, which can influence CD30′s stability and interaction with ligands, thereby affecting the overall immune response. Anti-CD30 antibody (B-10) serves as an essential tool for researchers studying the dynamics of immune cell activation and the pathogenesis of related diseases.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD30 Antibody (B-10) References:
- CD30 prevents T-cell responses to non-lymphoid tissues. | Heath, WR., et al. 1999. Immunol Rev. 169: 23-9. PMID: 10450505
- Deciphering CD30 ligand biology and its role in humoral immunity. | Kennedy, MK., et al. 2006. Immunology. 118: 143-52. PMID: 16771849
- The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas. | Macalalad, AR., et al. 2015. Curr Med Res Opin. 31: 537-45. PMID: 25598441
- CD30+ lymphoproliferative disorder with spindle-cell morphology. | Martires, KJ., et al. 2016. J Cutan Pathol. 43: 1041-1044. PMID: 27433975
- Brentuximab vedotin in CD30+ primary cutaneous T-cell lymphomas: a review and analysis of existing data. | Enos, TH., et al. 2017. Int J Dermatol. 56: 1400-1405. PMID: 28762479
- Nodal Involvement by CD30+ Cutaneous Lymphoproliferative Disorders and Its Challenging Differentiation From Classical Hodgkin Lymphoma. | Lezama, LS. and Gratzinger, D. 2018. Arch Pathol Lab Med. 142: 139-142. PMID: 29257929
- Intraindividual variability of CD30 expression in mycosis fungoides -implications for diagnostic evaluation and therapy. | Mitteldorf, C., et al. 2022. Histopathology. 81: 55-64. PMID: 35403270
- Advanced-Stage CD30+ Mycosis Fungoides Treated With Brentuximab. | Vico-Alonso, C., et al. 2022. Actas Dermosifiliogr. 113: 529-531. PMID: 35697415
- Novel OX40 and 4-1BB derived spacers enhance CD30 CAR activity and safety in CD30 positive lymphoma models. | Kua, L., et al. 2024. Mol Ther. 32: 3504-3521. PMID: 38946142
- Standardization of CD30 immunohistochemistry staining among three automated immunostaining platforms. | Seki, M., et al. 2024. Pathol Int. 74: 530-537. PMID: 39171823
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD30 Antibody (B-10) | sc-514271 | 200 µg/ml | $316.00 | |||
CD30 Antibody (B-10): m-IgG Fc BP-HRP Bundle | sc-538614 | 200 µg Ab; 10 µg BP | $354.00 | |||
CD30 Antibody (B-10): m-IgGκ BP-HRP Bundle | sc-536258 | 200 µg Ab; 40 µg BP | $354.00 | |||
CD30 (B-10) Neutralizing Peptide | sc-514271 P | 100 µg/0.5 ml | $68.00 |